Vnitr Lek 2013, 59(12):1039-1040

Komentář ke studii EDGE - editorial

M. Honka
Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

Received: November 25, 2013; Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Honka M. Komentář ke studii EDGE - editorial. Vnitr Lek. 2013;59(12):1039-1040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bader G, Geransar P, Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA < 7.0 % without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Res Clin Pract 2013; 100: e78-e81. Go to original source... Go to PubMed...
    2. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequatelly controlled on metformine monotherapy. Diabetes Obes Metab 2009; 11: 157-166. Go to original source... Go to PubMed...
    3. Hazell L, Shakir SA. Under-reporting of adverse drug reactions a systematic review. Drug Saf 2006; 29: 385-396. Go to original source... Go to PubMed...
    4. Honka M. Kombinační terapie perorálními antidiabetiky - kombinace derivátů sulfonylurey a metforminu. Vnitř Lék 2006; 52 (Suppl 3):-50-54. Go to PubMed...
    5. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2012; 55: 1577-1596. Go to original source... Go to PubMed...
    6. Kvapil M. Inkretiny změnily a dále mění strategii léčby diabetu 2. typu. Vnitř Lék 2011; 57: 916-918. Go to PubMed...
    7. Mathieu C, Barnett AH, Brath H et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE). Int J Clin Pract 2013; 67:-947-956. Go to original source... Go to PubMed...
    8. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789. Go to original source... Go to PubMed...
    9. Perez Garcia M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiol Drug Saf 2011; 20: 1295-1302. Go to original source... Go to PubMed...
    10. Ware JH, Hamel MB. Pragmatic trials - guides to better patient care? N Engl J Med 2011; 364: 1685-1687. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.